AnaptysBio (NASDAQ:ANAB) Given Outperform Rating at Wedbush

Wedbush reissued their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note issued to investors on Thursday morning,RTT News reports. The brokerage currently has a $42.00 target price on the biotechnology company’s stock.

ANAB has been the topic of several other reports. Guggenheim lifted their target price on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, October 21st. JPMorgan Chase & Co. cut their price objective on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. UBS Group increased their target price on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. HC Wainwright cut their price target on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Truist Financial increased their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $54.64.

AnaptysBio Price Performance

Shares of ANAB stock opened at $19.00 on Thursday. The stock has a market cap of $578.15 million, a PE ratio of -3.13 and a beta of -0.24. The stock has a 50-day moving average of $31.06 and a 200-day moving average of $29.91. AnaptysBio has a one year low of $13.36 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.72) by $0.58. The firm had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, research analysts anticipate that AnaptysBio will post -6.02 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. This represents a 8.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the transaction, the chief financial officer now owns 4,744 shares in the company, valued at approximately $189,333.04. The trade was a 72.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock valued at $892,936 in the last three months. 33.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC bought a new stake in shares of AnaptysBio in the 1st quarter valued at about $38,000. Values First Advisors Inc. bought a new stake in AnaptysBio in the third quarter valued at approximately $49,000. nVerses Capital LLC raised its stake in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares during the period. Headlands Technologies LLC lifted its position in shares of AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 2,900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 2,600 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.